ABSTRACT
Objective: In the present study, we are reporting the clinical profile;and outcomes of COVID-19 in patients with hematological malignancy at tertiary care hospitals. Methods: Data from laboratory-confirmed 40 COVID-19 patients diagnosed between January 1, 2021 and July 31, 2021, were analyzed retrospectively. All COVID-19 patients with hematological malignancy (n=40) were included in the study. Results: In the present study, a total of 40 patients were included. Of 40, 25 (62.5%) were males, and 15 (37.5%) were females. The median age in this study was 43 years (Range, 8–70). Of these 40 patients, acute myeloid leukemia was the most common malignancy 11 (27.5%), followed by acute lymphoblastic leukemia 9 (22.5%) than non-Hodgkin lymphoma 5 (12.5%), plasma cell dyscrasia 4 (10%), chronic myeloid leukemia 4 (10%), chronic lymphocytic leukemia 3 (7.5%), acute promyelocytic leukemia 2 (5%), chronic myelomonocytic leukemia 2 (5%). Mean hemoglobin was (8.04 g/dl), white blood cell count was (10.14×109/l), platelet count was (77.7×109/l) creatinine was (0.86 mg/dl), bilirubin was (1.24 mg/dl). The overall case-fatality rate was 8 (22.5%). Conclusion: Patients with hematological malignancy are immunocompromised, and our study reveals that there is an increased case fatality rate among these patients. Hence, physicians should be aggressive in the management of COVID-19 patients with hematological malignancy.
ABSTRACT
Introduction: The covid-19 pandemic had resulted in all thehealthcare infrastructure being diverted to the management of thepandemic. This has resulted in other diseases being side-lined. Thelong term consequence of this is yet to be known. In our study, weaimed to study how the diagnosis of covid changed the managementin hematological malignancies. We hope that the lessons learnt from this will help us manage the treatment of hematological malignanciesin a better way.Aims &Objectives: In this study, we aimed to report the clinicalprofile and outcomes of COVID-19 in patients with haematologicalmalignancy at a tertiary care hospital.Materials &Methods: It is an observational study. Data from laboratory-confirmed 40 COVID-19 patients diagnosed between 1January 2021 and 31 July 2021 were analysed retrospectively. AllCOVID-19 patients with haematological malignancy (n = 40) wereincluded in the study.Result: In this present study, total 40 patients were included. Of these,25(62.5%) were males and 15(37. 5%) were females. The median agein this study was 43 years. (Range, 8-70). Of these 40 patients, acutemyeloid Leukemia was the commonest malignancy (27.5%), followedby acute lymphoblastic Leukemia (22.5%) then non-Hodgkin lymphoma (12.5%), plasma cell dyscrasia (10%), chronic myeloid Leukemia (10%), chronic lymphocytic Leukemia (7.5%), acutepromyelocytic Leukemia (5%), chronic myelomonocytic Leukemia(5%). Mean hemoglobin was (8.04 gm/dl), WBC count was(10.14 × 109/l), platelet count was (77.7 × 109/l) creatinine was(0.86 mg/dl), bilirubin was (1.24 mg/dl). The median delay in initiating chemotherapy was 17 days. The average stay in the covid wardwas 12.8 days. Over all Case fatality rate was 22.5%. The meannumber of days for rt-pcr to turn negative was 11.2 days, with onepatient with severe covid remaining positive for 27 days. Thrombosiswas not seen in any of our patients even though malignancy and covidare both associated with increased thrombotic risk.Conclusions: Patients with haematological malignancy areimmunocompromised, and our study reveals that there is an increasedcase fatality rate among these patients. The delay in initiatingchemotherapy-both because of covid illness and also because oflimitation with initiating chemotherapy in the covid ward resulted in ahigher case mortality. Therefore, physicians should pay great attention to the management of COVID-19 patients with haematologicalmalignancy.